Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

Presentation TCT 2024

Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Coated Balloon Angioplasty in Complex Femoropopliteal Artery Disease: Primary Subgroup Analysis of the Randomized IVUS-DCB Trial

Presenter: Seung-Jun Lee

October 28, 2024

Presentation TCT 2024

TCT 696: Survival Benefit of Optimal Glycemic Control in Diabetic Patients Undergoing Endovascular Therapy for Femoropopliteal Disease

Presenter: Jae Young Jeung

October 28, 2024

Presentation TCT 2024

TCT 691: Endovascular Treatment of Femoropopliteal Peripheral Arterial Disease Lesions With the Novel Sirolimus-Coated Balloons: A Meta-Analysis

Presenter: Hamza Naveed

October 28, 2024

Presentation ACC 2024

Comparison of IVUS-guided vs. Angiography-guided Angioplasty for the Outcomes of DCB in the Treatment of Femoropopliteal Artery Disease

Presenter: Young-Guk Ko

April 08, 2024

Presentation TCT 2023

TCT 469: Optical coherence tomography predicts major adverse limb events in patients with femoropopliteal artery disease

Presenter: Donna Lin

October 25, 2023

Presentation TCT 2023

TCT 157: Sirolimus-Coated Balloon in Femoropopliteal Steno-Occlusive Disease: Efficacy, Safety and One-Year Outcomes. An All-Comers Registry.

Presenter: Marco Ferrone

October 24, 2023

Presentation TCT 2023

Percutaneous Transmural Bypass for Long and Complex Femoropopliteal Lesions: Clinical Outcomes of the DETOUR-2 Study

Presenter: Ajanta De

October 24, 2023

Presentation TCT 2022

TCT 209: Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Patients With Diabetes Mellitus: Results of the Randomized Chocolate Touch Study

Presenter: Sahil Parikh

September 17, 2022

Presentation TCT 2021

Directional Versus Orbital Atherectomy of Femoropopliteal Artery Lesions: Angiographic and Intravascular Ultrasound Outcomes

Presenter: Anvar Babaev

November 06, 2021

Presentation TCT 2021

Determinants of Drug-coated Balloon Failure in Femoropopliteal Intervention. Insights From a Patient-level Pooled Analysis

Presenter: Prakash Krishnan

November 06, 2021

Presentation TCT 2020

Where Are We With the Data on Paclitaxel?

Presenter: Eric Secemsky

October 18, 2020

Presentation TCT 2020

ILLUMENATE: Four-Year Results With a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions

Presenter: Andrew Holden

October 18, 2020

Presentation TCT 2020

TCT 366: Role of Embolic Protection Devices in Reducing Major Adverse Limb Events in Femoropopliteal Arterial Interventions in a Matched Cohort of Patients With Critical Limb Ischemia: Results From the XLPAD Registry.

Presenter: Qais Radaideh

October 14, 2020

Presentation TCT 2019

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

Presenter: Eric Secemsky

September 27, 2019

Presentation TCT 2019

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Presenter: Rebecca Ward

September 26, 2019

Presentation TCT 2019

Potential Study Designs to Address the Mortality Safety Signal

Presenter: Laura Mauri

September 26, 2019

Presentation TCT 2019

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Presenter: Sahil Parikh

September 26, 2019

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Advertisement

Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Coated Balloon Angioplasty in Complex Femoropopliteal Artery Disease: Primary Subgroup Analysis of the Randomized IVUS-DCB Trial

TCT 696: Survival Benefit of Optimal Glycemic Control in Diabetic Patients Undergoing Endovascular Therapy for Femoropopliteal Disease

TCT 691: Endovascular Treatment of Femoropopliteal Peripheral Arterial Disease Lesions With the Novel Sirolimus-Coated Balloons: A Meta-Analysis

Comparison of IVUS-guided vs. Angiography-guided Angioplasty for the Outcomes of DCB in the Treatment of Femoropopliteal Artery Disease

TCT 469: Optical coherence tomography predicts major adverse limb events in patients with femoropopliteal artery disease

TCT 157: Sirolimus-Coated Balloon in Femoropopliteal Steno-Occlusive Disease: Efficacy, Safety and One-Year Outcomes. An All-Comers Registry.

Percutaneous Transmural Bypass for Long and Complex Femoropopliteal Lesions: Clinical Outcomes of the DETOUR-2 Study

TCT 209: Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Patients With Diabetes Mellitus: Results of the Randomized Chocolate Touch Study

Directional Versus Orbital Atherectomy of Femoropopliteal Artery Lesions: Angiographic and Intravascular Ultrasound Outcomes

Determinants of Drug-coated Balloon Failure in Femoropopliteal Intervention. Insights From a Patient-level Pooled Analysis

Where Are We With the Data on Paclitaxel?

ILLUMENATE: Four-Year Results With a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions

TCT 366: Role of Embolic Protection Devices in Reducing Major Adverse Limb Events in Femoropopliteal Arterial Interventions in a Matched Cohort of Patients With Critical Limb Ischemia: Results From the XLPAD Registry.

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Potential Study Designs to Address the Mortality Safety Signal

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content